Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI.

IF 2.3 Q3 ONCOLOGY

Prostate Cancer Pub Date : 2020-04-03 eCollection Date: 2020-01-01 DOI:10.1155/2020/4626781

Maudy C W Gayet, Anouk A M A van der Aa, Harrie P Beerlage, Bart Ph Schrier, Maaike Gielens, Roel Heesakkers, Gerrit J Jager, Peter F A Mulders, Hessel Wijkstra

{"title":"Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI.","authors":"Maudy C W Gayet, Anouk A M A van der Aa, Harrie P Beerlage, Bart Ph Schrier, Maaike Gielens, Roel Heesakkers, Gerrit J Jager, Peter F A Mulders, Hessel Wijkstra","doi":"10.1155/2020/4626781","DOIUrl":null,"url":null,"abstract":"Objective: To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men.Methods: An in-patient control study of 82 men undergoing SB and subsequent TB in case of positive prostate MRI between 2015 and 2017 in the Jeroen Bosch Hospital, the Netherlands.Results: Prostate cancer (PCa) was detected in 54.9% with 70.7% agreement between TB and SB. Significant PCa (Gleason score ≥7) was detected in 24.4%. The CDR with TB and SB was 35.4% and 48.8%, respectively (p=0.052). The CDR of significant prostate cancer with TB and SB was both 20.7%. Clinically significant pathology upgrading occurred in 7.3% by adding TB to SB and 22.0% by adding SB to TB.Conclusions: There is no statistically significant difference between CDRs of SB and TB. Both SB and TB miss significant PCas. Moreover, pathology upgrading occurred more often by adding SB to TB than vice versa. This indicates that the omission of SB in this study population might not be justified.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2020 ","pages":"4626781"},"PeriodicalIF":2.3000,"publicationDate":"2020-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/4626781","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/4626781","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Objective: To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men.

Methods: An in-patient control study of 82 men undergoing SB and subsequent TB in case of positive prostate MRI between 2015 and 2017 in the Jeroen Bosch Hospital, the Netherlands.

Results: Prostate cancer (PCa) was detected in 54.9% with 70.7% agreement between TB and SB. Significant PCa (Gleason score ≥7) was detected in 24.4%. The CDR with TB and SB was 35.4% and 48.8%, respectively (p=0.052). The CDR of significant prostate cancer with TB and SB was both 20.7%. Clinically significant pathology upgrading occurred in 7.3% by adding TB to SB and 22.0% by adding SB to TB.

Conclusions: There is no statistically significant difference between CDRs of SB and TB. Both SB and TB miss significant PCas. Moreover, pathology upgrading occurred more often by adding SB to TB than vice versa. This indicates that the omission of SB in this study population might not be justified.

Abstract Image

查看原文本刊更多论文

双参数MRI后系统和靶向前列腺活检的癌症检出率。

目的:比较前列腺活检(TB)和系统前列腺活检(SB)对前列腺癌的检出率和病理结果。方法:对荷兰Jeroen Bosch医院2015年至2017年前列腺MRI阳性的82名接受SB和随后的TB的男性进行住院对照研究。结果:前列腺癌(PCa)检出率为54.9%，TB与SB检出率为70.7%，显著性PCa (Gleason评分≥7)检出率为24.4%。合并TB和SB的CDR分别为35.4%和48.8% (p=0.052)。显著性前列腺癌合并TB和SB的CDR均为20.7%。在TB和TB中分别加入SB和SB的病例中，有临床意义的病理升级的病例分别为7.3%和22.0%。结论:SB与TB的cdr差异无统计学意义。SB和TB都错过了重要的PCas。此外，将SB添加到TB中比将SB添加到TB中更容易发生病理升级。这表明在本研究人群中遗漏SB可能是不合理的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate Cancer ONCOLOGY-

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Prostate Cancer is a peer-reviewed, Open Access journal that provides a multidisciplinary platform for scientists, surgeons, oncologists and clinicians working on prostate cancer. The journal publishes original research articles, review articles, and clinical studies related to the diagnosis, surgery, radiotherapy, drug discovery and medical management of the disease.